Quality of life in Parkinson’s disease improved by apomorphine

The prevalence of Parkinson’s Disease in India is 300-400 out of 100,000, which is expected to double by 2030.Medica Superspecialty Hospital in association with Kings College, London and UK-based Britannia Pharmaceuticals, has launched a revolutionary treatment that will change the way Parkinson’s disease is being treated in eastern India. ‘Apomorphine Pen & Pump’ is the treatment that will radically change the life of a Parkinson’s patient.

Apomorphine is a highly selective Dopamine receptor emulator, which promotes the release of Dopamine in the brain from the nerve cells, explained Dr Sunandan Basu, Consultant Neurosurgeon, Medica Superspecialty Hospital.

While explaining further, Prof Kalyan Bhattacharya, Consultant Parkinson’s Disease and Movement Disorders Specialist, Medica Superspecialty Hospital said that DBS was not a choice for all ages & stages of Parkinson’s disease.  Hence there were limitations and there was a need for therapeutic options in moderately advanced Parkinson’s disease.

Dr. Vinod Metta, Consultant Interventional Neurologist, Kings College Hospital, London, & Medical advisor to Britannia Pharmaceuticals India, told that Apomorphine pens work dramatically on patients within a couple of minutes and are very similar to usage to that of Insulin Pens.